Red wine consumption and prevention of atherosclerosis: An in vitro model using human peripheral blood mononuclear cells

T. Magrone, A. Tafaro, F. Jirillo, M. A. Panaro, P. Cuzzuol, A. C. Cuzzuol, V. Pugliese, L. Amati, Emilio Jirillo, V. Covelli

Research output: Contribution to journalArticle

Abstract

Evidence has been provided that red wine possesses antiatherogenic activities in virtue of its content in polyphenols (flavonoids and non-flavonoids substances). Here, some red wines (Negroamaro, Primitivo and Lambrusco) were tested for their ability to trigger nitric oxide (NO) production from human healthy peripheral blood mononuclear cells (PBMC). Negroamaro was the strongest inducer of NO from PBMC and deprivation of polyphenols did not influence its NO generation capacity. This fact supports the involvement of polyphenols in the NO production even in the absence of alcohol, which also per se does not exert any significant activity. These results are also corroborated by the evidence that PBMC inducible-nitric oxide synthase expression occured by the effect of samples containing polyphenols but this expression was very weak when polyphenols were removed from the whole Negroamaro. In synthesis, flavonoids and resveratrol, major constitutents of red wine, once absorbed at intestinal level, enter circulabon and trigger monocytes for NO production. To the best of our knowledge, this is the first demonstration of a direct effect of red wine on monocytes for NO release to occur. On the other hand, also the macrophage contingent from gut-associated lymphoid tissue can contribute to NO generation, besides the aliquot produced by endothelial cells, as previously demonstrated by various authors. Taken together, these results support the concept that moderate intake of red wine can prevent atherosclerosis via production of NO, a potent vasodilator of terminal vessels.

Original languageEnglish
Pages (from-to)3718-3725
Number of pages8
JournalCurrent Pharmaceutical Design
Volume13
Issue number36
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Wine
Blood Cells
Atherosclerosis
Nitric Oxide
Polyphenols
Flavonoids
Monocytes
In Vitro Techniques
Lymphoid Tissue
Nitric Oxide Synthase Type II
Vasodilator Agents
Endothelial Cells
Macrophages
Alcohols

Keywords

  • Antiinflammatory
  • Atherosclerosis
  • Flavonoids
  • Inducible nitric oxide synthase
  • Nitric oxide
  • Peripheral blood mononuclear cells
  • Polyphenols
  • Red wine

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Magrone, T., Tafaro, A., Jirillo, F., Panaro, M. A., Cuzzuol, P., Cuzzuol, A. C., ... Covelli, V. (2007). Red wine consumption and prevention of atherosclerosis: An in vitro model using human peripheral blood mononuclear cells. Current Pharmaceutical Design, 13(36), 3718-3725. https://doi.org/10.2174/138161207783018581

Red wine consumption and prevention of atherosclerosis : An in vitro model using human peripheral blood mononuclear cells. / Magrone, T.; Tafaro, A.; Jirillo, F.; Panaro, M. A.; Cuzzuol, P.; Cuzzuol, A. C.; Pugliese, V.; Amati, L.; Jirillo, Emilio; Covelli, V.

In: Current Pharmaceutical Design, Vol. 13, No. 36, 12.2007, p. 3718-3725.

Research output: Contribution to journalArticle

Magrone, T, Tafaro, A, Jirillo, F, Panaro, MA, Cuzzuol, P, Cuzzuol, AC, Pugliese, V, Amati, L, Jirillo, E & Covelli, V 2007, 'Red wine consumption and prevention of atherosclerosis: An in vitro model using human peripheral blood mononuclear cells', Current Pharmaceutical Design, vol. 13, no. 36, pp. 3718-3725. https://doi.org/10.2174/138161207783018581
Magrone, T. ; Tafaro, A. ; Jirillo, F. ; Panaro, M. A. ; Cuzzuol, P. ; Cuzzuol, A. C. ; Pugliese, V. ; Amati, L. ; Jirillo, Emilio ; Covelli, V. / Red wine consumption and prevention of atherosclerosis : An in vitro model using human peripheral blood mononuclear cells. In: Current Pharmaceutical Design. 2007 ; Vol. 13, No. 36. pp. 3718-3725.
@article{0635df37af6144278aaa013f11f04208,
title = "Red wine consumption and prevention of atherosclerosis: An in vitro model using human peripheral blood mononuclear cells",
abstract = "Evidence has been provided that red wine possesses antiatherogenic activities in virtue of its content in polyphenols (flavonoids and non-flavonoids substances). Here, some red wines (Negroamaro, Primitivo and Lambrusco) were tested for their ability to trigger nitric oxide (NO) production from human healthy peripheral blood mononuclear cells (PBMC). Negroamaro was the strongest inducer of NO from PBMC and deprivation of polyphenols did not influence its NO generation capacity. This fact supports the involvement of polyphenols in the NO production even in the absence of alcohol, which also per se does not exert any significant activity. These results are also corroborated by the evidence that PBMC inducible-nitric oxide synthase expression occured by the effect of samples containing polyphenols but this expression was very weak when polyphenols were removed from the whole Negroamaro. In synthesis, flavonoids and resveratrol, major constitutents of red wine, once absorbed at intestinal level, enter circulabon and trigger monocytes for NO production. To the best of our knowledge, this is the first demonstration of a direct effect of red wine on monocytes for NO release to occur. On the other hand, also the macrophage contingent from gut-associated lymphoid tissue can contribute to NO generation, besides the aliquot produced by endothelial cells, as previously demonstrated by various authors. Taken together, these results support the concept that moderate intake of red wine can prevent atherosclerosis via production of NO, a potent vasodilator of terminal vessels.",
keywords = "Antiinflammatory, Atherosclerosis, Flavonoids, Inducible nitric oxide synthase, Nitric oxide, Peripheral blood mononuclear cells, Polyphenols, Red wine",
author = "T. Magrone and A. Tafaro and F. Jirillo and Panaro, {M. A.} and P. Cuzzuol and Cuzzuol, {A. C.} and V. Pugliese and L. Amati and Emilio Jirillo and V. Covelli",
year = "2007",
month = "12",
doi = "10.2174/138161207783018581",
language = "English",
volume = "13",
pages = "3718--3725",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "36",

}

TY - JOUR

T1 - Red wine consumption and prevention of atherosclerosis

T2 - An in vitro model using human peripheral blood mononuclear cells

AU - Magrone, T.

AU - Tafaro, A.

AU - Jirillo, F.

AU - Panaro, M. A.

AU - Cuzzuol, P.

AU - Cuzzuol, A. C.

AU - Pugliese, V.

AU - Amati, L.

AU - Jirillo, Emilio

AU - Covelli, V.

PY - 2007/12

Y1 - 2007/12

N2 - Evidence has been provided that red wine possesses antiatherogenic activities in virtue of its content in polyphenols (flavonoids and non-flavonoids substances). Here, some red wines (Negroamaro, Primitivo and Lambrusco) were tested for their ability to trigger nitric oxide (NO) production from human healthy peripheral blood mononuclear cells (PBMC). Negroamaro was the strongest inducer of NO from PBMC and deprivation of polyphenols did not influence its NO generation capacity. This fact supports the involvement of polyphenols in the NO production even in the absence of alcohol, which also per se does not exert any significant activity. These results are also corroborated by the evidence that PBMC inducible-nitric oxide synthase expression occured by the effect of samples containing polyphenols but this expression was very weak when polyphenols were removed from the whole Negroamaro. In synthesis, flavonoids and resveratrol, major constitutents of red wine, once absorbed at intestinal level, enter circulabon and trigger monocytes for NO production. To the best of our knowledge, this is the first demonstration of a direct effect of red wine on monocytes for NO release to occur. On the other hand, also the macrophage contingent from gut-associated lymphoid tissue can contribute to NO generation, besides the aliquot produced by endothelial cells, as previously demonstrated by various authors. Taken together, these results support the concept that moderate intake of red wine can prevent atherosclerosis via production of NO, a potent vasodilator of terminal vessels.

AB - Evidence has been provided that red wine possesses antiatherogenic activities in virtue of its content in polyphenols (flavonoids and non-flavonoids substances). Here, some red wines (Negroamaro, Primitivo and Lambrusco) were tested for their ability to trigger nitric oxide (NO) production from human healthy peripheral blood mononuclear cells (PBMC). Negroamaro was the strongest inducer of NO from PBMC and deprivation of polyphenols did not influence its NO generation capacity. This fact supports the involvement of polyphenols in the NO production even in the absence of alcohol, which also per se does not exert any significant activity. These results are also corroborated by the evidence that PBMC inducible-nitric oxide synthase expression occured by the effect of samples containing polyphenols but this expression was very weak when polyphenols were removed from the whole Negroamaro. In synthesis, flavonoids and resveratrol, major constitutents of red wine, once absorbed at intestinal level, enter circulabon and trigger monocytes for NO production. To the best of our knowledge, this is the first demonstration of a direct effect of red wine on monocytes for NO release to occur. On the other hand, also the macrophage contingent from gut-associated lymphoid tissue can contribute to NO generation, besides the aliquot produced by endothelial cells, as previously demonstrated by various authors. Taken together, these results support the concept that moderate intake of red wine can prevent atherosclerosis via production of NO, a potent vasodilator of terminal vessels.

KW - Antiinflammatory

KW - Atherosclerosis

KW - Flavonoids

KW - Inducible nitric oxide synthase

KW - Nitric oxide

KW - Peripheral blood mononuclear cells

KW - Polyphenols

KW - Red wine

UR - http://www.scopus.com/inward/record.url?scp=37449022414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37449022414&partnerID=8YFLogxK

U2 - 10.2174/138161207783018581

DO - 10.2174/138161207783018581

M3 - Article

C2 - 18220811

AN - SCOPUS:37449022414

VL - 13

SP - 3718

EP - 3725

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 36

ER -